Hai cercato la traduzione di her hand was small da Inglese a Maltese

tom grabbed her hand.
tlaqna ħdejha!” !”

she had only been working for an hour when her hand was dragged into the machine.
kienet ilha biss siegħa taħdem meta idha nġibdet għal ġol-magna.

in clinical trials the effect on qtc was small (mean of approximately 1 msec).
fi provi kliniċi , l-effett fuq il-qtc kien żgħir (medja ta’ madwar 1 msec).

the inter-subject coefficient of variation for alogliptin auc was small (17%).
il-koeffiċjent ta’ varjabilità bejn individwu u ieħor għal alogliptin auc kien żgħir (17%).

priority treatment, on the other hand, was granted in one case.
barraminn hekk, f’kawża waħda ġie aċċettat li din tingħata prijorità fuq il-kawżi l-oħra.

iee was small in relation to the market (for energy) which it was intended to influence.
l-iee kien żgħir b’relazzjoni mas-suq (għall-enerġija) li kien bi ħsiebu jinfluwenza.

priority treatment, on the other hand, was granted in eight cases.
barra minn hekk, ‘ 8 kawżi ġie aċċettat li dawn il-kawżi jingħataw prijorità fuq il-kawżi l-oħra.

however, the sample size was small, there was no significant interaction and the ci was wide and included the hr for os of the overall adenocarcinoma population.
madankollu, id-daqs tal-kampjun kien żgħir, u ma kien hemm l-ebda interazzjoni sinifikanti u s-ci kien wiesgħa u kien jinkludi l-hr għal os tal-popolazzjoni globali b'adenokarċinoma.

the committee took the view that although the improvement in fev1 shown by the studies was small bronchitol may be of benefit in patients with cystic fibrosis if used in addition to best standard of care.
il-kumitat iddeċieda li għad li t-titjib f’fev1 muri mill-istudji kien żgħir, bronchitol jista’ jkun ta’ benefiċċju f’pazjenti b’fibrożi ċistika jekk jintuża flimkien mal-aħjar standard ta’ kura.

although the main study was small and did not directly compare strensiq with another treatment or with untreated patients, the chmp considered that the improvement seen in the bones and the apparent growth was relevant.
għalkemm l-istudju ewlieni huwa żgħir u ma pparagunax direttament strensiq ma' kuri oħrajn jew ma pazjenti mhux ikkurati, is-chmp ikkunsidra li t-titjib li deher fl-għadam u t-tkabbir evidenti kien rilevanti.

however the improvement over formoterol alone was small and not considered clinically significant: fev1 measured in the morning before the inhalation was 68 ml more with brimica genuair than with formoterol alone.
madankollu, it-titjib meta mqabbel ma’ formoterol waħdu kien żgħir u mhux meqjus klinikament sinifikanti: fev1 imkejjel filgħodu qabel it-teħid man-nifs kien 68 ml aktar bi brimica genuair milli b’formoterol waħdu.

although the committee noted that the study in patients not on dialysis was small, it concluded that the medicine can also be used in these patients because they have the same underlying disease as those on dialysis and therefore similar effectiveness can be expected.
għalkemm il-kumitat innota li l-istudju fil-pazjenti mhux fuq dijaliżi kien żgħir, ikkonkluda li l-mediċini jistgħu jintużaw ukoll f’dawn il-pazjenti minħabba li għandhom l-istess mard sottostanti bħal dawk fuq dijaliżi u għalhekk tista’ tiġi mistennija effikaċja simili.

overall, results from the clinical program to date do not suggest an increased risk for malignancy with vedolizumab treatment; however, the number of malignancies was small and long-term exposure was limited.
b’mod globali, riżultati mill-programm kliniku s’issa ma jissuġġerixxux żieda fir-riskju ta’ tumuri malinni b’kura ta’ vedolizumab; madankollu, in-numru ta’ tumuri malinni kien żgħir u l-esponiment fit-tul kien limitat.

in-vitro studies indicate that the effect of ertapenem on the plasma protein binding of highly protein bound medicinal products (warfarin, ethinyl estradiol, and norethindrone) was small.
studji in- vitro jindikaw li l- effett ta 'ertapenem fuq il- ħila ta' l- irbit mal- proteini tal- plażma fi prodotti mediċinali li għandhom irbit qawwi mal- proteini (warfarin, ethinyl estradiol, norethindrone) huwa żgħir.

although the additional time spent in sunlight was small, the committee considered the possible improvements in quality of life, the unmet medical need in patients with epp, and the mild side effects seen during short-term treatment with the medicine in deciding to recommend approval for scenesse in the eu.
għalkemm il-ħin addizzjonali li qattgħu fid-dawl tax- xemx kien qasir, il-kumitat ikkunsidra t-titjib possibbli fil-kwalità tal-ħajja, il-ħtieġa medika mhux sodisfatta f’pazjenti b’epp, u l-effetti sekondarji ħfief li dehru waqt il-kura għal żmien qasir bil-mediċina fid-deċiżjoni ta’ rakkomandazzjoni tal-approvazzjoni għal scenesse fl-ue.

moreover, in the pooled population, invega was not efficacious in patients concomitantly receiving mood stabiliser and antidepressants in regard to the psychotic symptoms, but this population was small (30 responders in the paliperidone group and 20 responders in the placebo group).
barra dan, fil-popolazzjoni miġbura flimkien, invega ma kienx effikaċi fir-rigward tas-sintomi psikotiċi f’pazjenti li kienu qed jirċievu stabilizzatur tal-burdata flimkien ma’ antidipressanti, iżda din il-popolazzjoni kienet żgħira (30 individwu li rrispondew għall-kura fil-grupp ta’ paliperidone u 20 individwu li rrispondew għall-kura fil-grupp ta’ plaċebo).

within the 42-day postvaccination reporting period in the sps, the number of reported zosteriform rashes among all subjects was small (17 for zostavax, 36 for placebo; p=0.009).
fi żmien 42 jum wara l- perjodu ta 'rapportar tat- tilqima fl- sps, in- numru ta' raxxijiet zosteriform irrapportati fost is- suġġetti kollha kien żgħir (17 għal zostavax, 36 għal placebo; p=0. 009).